Sign up
Pharma Capital

Medlab Clinical progresses through trials, overseas registration process

Medlab Clinical (ASX:MDC) has completed the first stage medical trials of its NanaBis product, and is encouraged by its progress with US and European medical registration administrations.

CEO Sean Hall distinguishes Medlab Clinical (ASX:MDC) from other "pot stocks" through its focus on proven medical outcomes and its breadth of products.

Hall says the company has sizeable upside as potential applications for its product include not only pain treatments but also other chronic health issues such as Type II Diabetes and depression.

 

View full MDC profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.